The Administrator of Drug and Controlled Substances Affairs of the Food and Drug Organization Visited Pars Isotope Company.

Dr. Mohammad Peikanpour, administrator of drug and controlled substances of the Food and Drug Organization, together with his first deputy and Dr. Davoud Beiki, nuclear medicine specialist and the head of Nuclear Medicine Research Center of Tehran University of Medical Sciences, visited the production line of radiopharmaceuticals and radiopharmaceutical kits of Pars Isotope Co. and the Tetra Project.

During this visit, which lasted for about 5 hours, the CEO of Pars Isotope along with the managers of production, quality assurance and public relations departments provided Dr. Peikanpour with explanations about the way of operation, types of produced radiopharmaceuticals and the usage of products. Furthermore, an effective visit was made to the production line of Pars Isotope reactor radiopharmaceuticals and radiopharmaceutical kits, as well as the production and development project of Iran’s radiopharmaceuticals known as ((Tetra)).

Dr. Peikanpour, while thanking the extensive production and research activities of Pars Isotope in the field of radiopharmaceuticals as the exclusive producer and supplier of radiopharmaceuticals and radiopharmaceutical kits in Iran, regarding the applications of radiopharmaceuticals and the service they provide to more than 200 nuclear medicine centers of the country in the field of diagnosis and treatment of various types of diseases and cancers, expressed pleasure and hopefulness. He also expressed his satisfaction while visiting the Tetra project, which is under construction according to the latest international and European standards, and he stated:” with the opening of the Tetra project and the export of more radiopharmaceuticals, Iran will become one of the leading countries in exporting radiopharmaceuticals.”